Ensuring Best Access to CF Treatment
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests whether people with cystic fibrosis who are already on a triple combination CFTR modulator can stay on their treatment without interruptions or problems. It aims to make sure everyone gets the best, most consistent treatment for their CF.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with cystic fibrosis (CF) and have a known type of CF gene change.
- You are 2 years old or older.
- You have been taking a stable dose of a triple combination CFTR modulator (like Trikafta) for at least 2 weeks before the study starts.
- Your lung disease has been stable—no big drop in lung function or need for extra antibiotics in the past 4 weeks.
- You can understand and agree to the study procedures, either yourself or with a parent/guardian.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the drug Trikafta (also called Kaftrio) works in children aged 2 to 17 with cystic fibrosis. The goal is to learn how the body processes the medicine so doctors can find the best dose.
This study looks at how the triple combination therapy (elexacaftor/tezacaftor/ivacaftor, or ETI) affects your body's metabolism, epigenetics, and gut bacteria in people with cystic fibrosis. It aims to understand the broader health benefits of this treatment.
This study measures how antibiotics are processed by the body in people with cystic fibrosis who are taking a combination drug called elexacaftor/tezacaftor/ivacaftor (ETI). Understanding this helps doctors prescribe the right antibiotic doses for patients on this newer treatment.
This study tests whether a special nutrition supplement can help people with cystic fibrosis who also have pancreatic problems. It is for adults 18 and older who are already taking a CFTR modulator and have normal liver lab results.
This study uses advanced diagnostic tests to help people whose cystic fibrosis (CF) diagnosis is unclear. It aims to give a clearer answer about whether you have CF or a related condition.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
Hear when a new Cystic Fibrosis (CF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.